Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.

Kohli MA, Farkouh RA, Maschio MJ, McGarry LJ, Strutton DR, Weinstein MC.

Health Aff (Millwood). 2015 Jul 1;34(7):1234-40. doi: 10.1377/hlthaff.2014.1274.

PMID:
26135209
2.

Rethinking risk for pneumococcal disease in adults: the role of risk stacking.

Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J.

Open Forum Infect Dis. 2015 Mar 20;2(1):ofv020. doi: 10.1093/ofid/ofv020. eCollection 2015 Jan.

3.

Rates of pneumococcal disease in adults with chronic medical conditions.

Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI.

Open Forum Infect Dis. 2014 May 27;1(1):ofu024. doi: 10.1093/ofid/ofu024. eCollection 2014 Mar.

4.

Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine.

Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J.

Clin Infect Dis. 2014 Sep 1;59(5):615-23. doi: 10.1093/cid/ciu348. Epub 2014 May 13.

PMID:
24825867
5.

Letter to the editor.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Jul;35(7):1048-50. doi: 10.1016/j.clinthera.2013.05.010. Epub 2013 Jun 24. No abstract available.

PMID:
23806326
6.

Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.

McGarry LJ, Gilmore KE, Rubin JL, Klugman KP, Strutton DR, Weinstein MC.

BMC Infect Dis. 2013 May 21;13:229. doi: 10.1186/1471-2334-13-229.

7.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
8.

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.

Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR.

Expert Rev Vaccines. 2012 Oct;11(10):1235-47. doi: 10.1586/erv.12.99. Epub 2012 Nov 21. Review.

PMID:
23170992
9.

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.

Strutton DR, Farkouh RA, Rubin JL, McGarry LJ, Loiacono PM, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC.

BMC Infect Dis. 2012 Aug 3;12:175. doi: 10.1186/1471-2334-12-175.

10.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.

Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, Klok R, Papanicolaou S.

J Infect. 2012 Jan;64(1):54-67. doi: 10.1016/j.jinf.2011.10.015. Epub 2011 Nov 4.

PMID:
22085813
11.

Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US.

Shea KM, Weycker D, Stevenson AE, Strutton DR, Pelton SI.

Vaccine. 2011 Oct 19;29(45):8042-8. doi: 10.1016/j.vaccine.2011.08.057. Epub 2011 Aug 24.

PMID:
21871518
12.

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.

Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC.

Vaccine. 2010 Nov 10;28(48):7634-43. doi: 10.1016/j.vaccine.2010.09.049. Epub 2010 Sep 28.

PMID:
20883739
13.

Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.

Rubin JL, McGarry LJ, Klugman KP, Strutton DR, Gilmore KE, Weinstein MC.

BMC Infect Dis. 2010 Jan 21;10:14. doi: 10.1186/1471-2334-10-14.

14.

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.

Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR.

Vaccine. 2009 Nov 5;27(47):6483-94. doi: 10.1016/j.vaccine.2009.08.045. Epub 2009 Aug 29.

PMID:
19720366
15.

Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations.

Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF.

Vaccine. 2009 Jul 23;27(34):4694-703. doi: 10.1016/j.vaccine.2009.05.062. Epub 2009 Jun 9.

PMID:
19520197
16.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
17.

Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia.

Strutton DR, Gutierrez B, Blanchette CM.

Am J Health Syst Pharm. 2008 Jan 1;65(1):42-8.

PMID:
18159038
18.

US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey.

Strutton DR, Kowalski JW, Glaser DA, Stang PE.

J Am Acad Dermatol. 2004 Aug;51(2):241-8.

PMID:
15280843
19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk